MOL Gets More Time to Negotiate Acquisition of Russian-Owned Stake in Serbia’s NIS 
Lululemon Cuts 2026 Outlook as Weak North America Sales Pressure Growth 
Airbus Aircraft Deliveries Surge in May 2026 
Trump Administration Defends Anthropic AI Restrictions in Ongoing Federal Lawsuit 
Apollo Ends Pursuit of Bodycote, Withdraws £1.52 Billion Takeover Proposal 
Italy’s ITA Airways Weighs Legal Action Against Pratt & Whitney Over Grounded Airbus Fleet 
Asics Considers Onitsuka Tiger Spinoff as Luxury Sneaker Brand Expands Globally 
J.P. Morgan Sees Major Upside for Prysmian as Optical Fiber Prices Surge 
ASIC Launches Formal Investigation Into KPMG Australia Partners Over Client Data Misuse Allegations 
Nvidia Expands South Korea AI Partnerships to Strengthen Data Center and Memory Chip Supply 
Foreign Firms Cash In on India's IPO Boom 
Apple Unveils Enhanced Apple Intelligence and Next-Generation Siri at WWDC 2026 
Honda Leadership Crisis Deepens as Retired Executives Challenge CEO Toshihiro Mibe’s Strategy 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Qualcomm Stock Gains After Jensen Huang Endorsement 
Apollo and Blackstone Complete $35 Billion Anthropic AI Infrastructure Financing Deal 
oOh!media Takeover Battle Intensifies as Bain Capital Joins Competing Bids 
Pfizer Inc. revealed that it received informal requests relating to its operations in China from the US Department of Justice and the US Securities and Exchange Commission (SEC) in June and August.
According to Pfizer, it is producing records to satisfy requests for documents from the Foreign Corrupt Practices Act units of the Justice Department and the SEC.
The 1977 Foreign Corrupt Practices Act makes it illegal for US firms and those whose stock is traded in the US to bribe foreign government officials.
In 2012, the drugmaker had to shell out $26.3 million as a settlement for illegal payments in winning overseas deals, including those in Russia, Bulgaria, China, the Middle East, and Italy.
China is a big growth market for global pharmaceutical companies. But they have to face tightened regulations, heightened tensions between China and the US, and China’s efforts to promote local generic drugmakers.
